Oral ingestion of Ginkgo biloba extract reduces thiobarbituric acid reacting (TBAR) substances in washed platelets of healthy subjects

Journal of Herbal Pharmacotherapy

Volumn 3, Issue 4, 2003, Pages 1-15

  Kudolo, George B ^a   Wang, Wen ^a   Dorsey, Sheryl ^b   Blodgett, Janet ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Free radical scavengers; Ginkgo biloba; Malondialdehyde; Platelets

Indexed keywords

CHOLESTEROL; CYCLOOXYGENASE 1; GINKGO BILOBA EXTRACT; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE;

EID: 0346402893     PISSN: 15228940     EISSN: None     Source Type: Journal    
DOI: 10.1300/J157v03n04_01     Document Type: Article

References (28)

1. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomised trial of an extract of Ginkgo biloba for dementia. JAMA 1997; 278: 1327-32.
2. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55: 1409-15.
3. Moulton PL, Boyko LN, Fitzpatrick JL. Petros TV. The effect of Ginkgo biloba on memory in healthy male volunteers. Physiol Behav 2001;73:659-65.
4. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement. A randomized controlled trial. JAMA 2002; 288:835-40.
5. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34:352-8.
6. Guinot P, Caffrey E, Lambe R, Darragh A. Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. Haemostasis 1989; 19:219-23.
7. Tzeng S-H, Ko W-C, Ko F-N, Teng C-M. Inhibition of platelet aggregation by some flavonoids. Thom Res 1991; 64:90-100.
8. Sobol A, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract Suppl 2000; 50:1-16.
9. 2/prostacyclin balance reflects the pathological state of a diabetic. Prostaglandins Other Lipid Mediat 1999;58:263-71.
10. Gryglewski RJ, Korbut R, Robak J, Swies J. On the mechanism of anti-thrombotic action of flavonoids. Biochem Pharmacol 1987;36:317-22.
11. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclo-oxygenases) -1 and -2. J Biol Chem 1996; 271:33157-60.
12. Inder TE, Darlow BA, Slius KB, Winterbourn CC, Graham P, Sanderson KJ, Taylor BJ. The correlation of elevated levels of an index of lipid peroxidation (MDA-TBA) with adverse outcome in the very low birth weight infant. Acta Paediatr 1996; 85:1116-22.
13. Smith LH, Boutand O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002; 22:983-8.
14. Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and type 2 diabetic subjects. Throm Res 2003; 108:151-60.
15. Niehaus WG Jr. Samuelson B. Formation of malonaldehyde from phospholipids arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968; 6:126-30.
16. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic β-cell function in response to glucose loading in healthy volunteers. J Clin Pharmacol 2000; 40:647-54.
17. Kudolo GB. The effect of 3-month ingestion of Ginkgo bilobo extract (EGb 761) on pancreatic β-cell function in response to glucose loading in individuals with non-insulin dependent diabetes mellitus. J Clin Pharmacol 2001; 41:600-11.
18. 2 synthesis. Alternative Therapies in Health and Medicine 2001; 7:105.
19. 2 synthesis in platelets from type 2 diabetic subjects. 2nd International Scientific Conference on Complementary, Alternative and Integrative Medicine Research. Boston, MA. April 11-16, 2002.
20. Van Wauwe J, Goossens J. Effects of antioxidants on cyclooxygenase and lipoxnase activities in intact human platelets: comparison with indomethacin and ETYA. Prostaglandins 1983; 26:725-30.
21. Chi YS, Jong HG, Son KH, Chang HW. Kang SS, Kim HP. Effects of naturally occurring prenylate flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem Pharcol 2001; 62:1185-91.
22. 2+ loaded brain neurons. Brain Res 1994; 635:125-9.
23. Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb761. Biochem Pharmacol 1995:49:1649-55.
24. Pasquale P, Pulcinelli FM, Celestini A, Lenti L, Ghiselli A, Gazzaniga PP, Violi F. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr 2000; 72:1150-5.
25. Carvahlo AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinnemia. N Engl J Med 1974; 290:434-48.
26. Harrison JE, Saeed FA. Radical acetoacetate oxidation by myeloperoxidase, lactoperoxidase, prostaglandin synthetase, and prostacyclin synthetase: implications for atherosclerosis. Biochem Med 1983; 29:149-63.
27. Walach H. The efficacy paradox in randomized controlled trials of CAM and elsewhere: beware of the placebo trap. J Altern Complement Med 2001; 7:213-8.
28. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin L. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71:1085-94.